Takashina et al. investigated the impact of CYP3A5 on fentanyl pharmacokinetics among 60 Japanese cancer patients undergoing conversion to a transdermal fentanyl from a previous treatment of either oral morphine or oxycodone [25]. The gene discussed is CYP3A5; the disease is cancer.